Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP564049.RAV0bfz5Ma1YU0aO2VI2GNjulJpzzE1HIoYsl063jIf5U130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP564049.RAV0bfz5Ma1YU0aO2VI2GNjulJpzzE1HIoYsl063jIf5U130_assertion type Assertion NP564049.RAV0bfz5Ma1YU0aO2VI2GNjulJpzzE1HIoYsl063jIf5U130_head.
- NP564049.RAV0bfz5Ma1YU0aO2VI2GNjulJpzzE1HIoYsl063jIf5U130_assertion description "[Treatment of CaCO-2 cells with rosiglitazone, a peroxisome proliferator-activated receptor-gamma (PPAR-gamma) agonist, significantly reduced secretion of MMP-9, indicating that agents that activate PPAR-gamma may have therapeutic use in patients with IBD.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP564049.RAV0bfz5Ma1YU0aO2VI2GNjulJpzzE1HIoYsl063jIf5U130_provenance.
- NP564049.RAV0bfz5Ma1YU0aO2VI2GNjulJpzzE1HIoYsl063jIf5U130_assertion evidence source_evidence_literature NP564049.RAV0bfz5Ma1YU0aO2VI2GNjulJpzzE1HIoYsl063jIf5U130_provenance.
- NP564049.RAV0bfz5Ma1YU0aO2VI2GNjulJpzzE1HIoYsl063jIf5U130_assertion SIO_000772 11244573 NP564049.RAV0bfz5Ma1YU0aO2VI2GNjulJpzzE1HIoYsl063jIf5U130_provenance.
- NP564049.RAV0bfz5Ma1YU0aO2VI2GNjulJpzzE1HIoYsl063jIf5U130_assertion wasDerivedFrom befree-20150227 NP564049.RAV0bfz5Ma1YU0aO2VI2GNjulJpzzE1HIoYsl063jIf5U130_provenance.
- NP564049.RAV0bfz5Ma1YU0aO2VI2GNjulJpzzE1HIoYsl063jIf5U130_assertion wasGeneratedBy ECO_0000203 NP564049.RAV0bfz5Ma1YU0aO2VI2GNjulJpzzE1HIoYsl063jIf5U130_provenance.